Business Context and Reporting Period
This Form 8-K Current Report was filed by DiaMedica Therapeutics Inc. on October 24, 2019. The company is incorporated in British Columbia and its common shares trade on The Nasdaq Stock Market under the symbol DMAC. The report addresses corporate governance changes under Item 5.02.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
- Departure: Todd Verdoorn, Ph.D., resigned as Chief Scientific Officer, effective November 15, 2019.
- Appointment: Sydney Gilman, Ph.D., was hired as Vice President, Regulatory Affairs, effective November 1, 2019.
Management Commentary and Background
Dr. Gilman brings significant regulatory experience to the company. He is the founder and President of Trident Rx Consulting Services LLC (since 2004) and previously served as a Chemistry reviewer at the U.S. Food and Drug Administration (FDA) for six years. He possesses 20 years of pharmaceutical industry experience and had been providing regulatory consulting services to DiaMedica since June 2019.
Investor Verification Checklist
- Confirm the effective dates of the C.S.O. resignation and the new V.P. of Regulatory Affairs appointment.
- Review the company's pipeline status to assess the impact of the Chief Scientific Officer departure on ongoing drug development.
- Verify Dr. Gilman's prior consulting relationship with the company to understand the transition from consultant to employee.